Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 4Phase 1 3Phase 3 2

Status

Recruiting 6Active not recruiting 3Completed 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3

Interventions

pembrolizumab 86Cyclophosphamide 75Nivolumab 55Specimen Handling 49fludarabine 48Magnetic Resonance Spectroscopy 44Carboplatin 41Biopsy 39Radiotherapy 32fludarabine phosphate 29Gemcitabine 28venetoclax 27atezolizumab 26Paclitaxel 26Ipilimumab 26Radiation 22Dexamethasone 22Cisplatin 22Radiosurgery 21durvalumab 20Rituximab 20Lenalidomide 19Temozolomide 17Bevacizumab 17Pemetrexed 15Decitabine 15Cytarabine 15130-nm albumin-bound paclitaxel 15palbociclib 14ibrutinib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Active not recruiting × Pluvicto × Clear all
NCT06303713 2026-04-08

LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
37 enrolled
Genitourinary

Prostatic Neoplasms

NCT05079698 2026-04-07

A Study of Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
29 enrolled
Genitourinary

Prostatic Neoplasms

NCT04886986 2026-03-31

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Weill Medical College of Cornell University

Phase 1 Active not recruiting
20 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡